Innovent Biologics Inc. (HKG: 1801) has announced an expanded partnership with U.S.-based Synaffix B.V., a subsidiary of Lonza (SWX: LONN). This follows an initial agreement from June 2021, during which Innovent successfully utilized Synaffix’s antibody-drug conjugate (ADC) technology platforms on a non-exclusive basis to develop IBI343, an anti-CLDN18.2 ADC that has now progressed to Phase I clinical trials.
The newly expanded agreement grants Innovent the rights to develop at least one additional ADC candidate, leveraging Synaffix’s ADC technologies. Innovent will retain research, development, manufacturing, and commercialization rights for any new ADCs created under this partnership. In return, Innovent will make undisclosed upfront and milestone payments to Synaffix, along with royalties from future sales.
Synaffix’s ADC platform incorporates GlycoConnect, HydraSpace, and toxSYN linker-payload technologies, which enhance therapeutic efficacy and tolerability while streamlining the development process. Synaffix’s clientele includes notable biopharmaceutical companies such as Shanghai Miracogen, Genmab, Amgen, and Kyowa Kirin.- Flcube.com
